JP2006524057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524057A5 JP2006524057A5 JP2006513191A JP2006513191A JP2006524057A5 JP 2006524057 A5 JP2006524057 A5 JP 2006524057A5 JP 2006513191 A JP2006513191 A JP 2006513191A JP 2006513191 A JP2006513191 A JP 2006513191A JP 2006524057 A5 JP2006524057 A5 JP 2006524057A5
- Authority
- JP
- Japan
- Prior art keywords
- plasmid
- acid sequence
- nucleic acid
- kit
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 101710091045 Envelope protein Proteins 0.000 claims description 4
- 101710188315 Protein X Proteins 0.000 claims description 4
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 4
- 102100036537 von Willebrand factor Human genes 0.000 claims description 4
- 229960001134 von willebrand factor Drugs 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 claims description 2
- 101800001271 Surface protein Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 49
- 239000013612 plasmid Substances 0.000 claims 40
- 239000002245 particle Substances 0.000 claims 23
- 230000003612 virological effect Effects 0.000 claims 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 20
- 150000007523 nucleic acids Chemical group 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 239000013598 vector Substances 0.000 claims 15
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 206010059866 Drug resistance Diseases 0.000 claims 5
- 108020005091 Replication Origin Proteins 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 4
- 239000002609 medium Substances 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 108090000404 Cyclin G1 Proteins 0.000 claims 3
- 102000004012 Cyclin G1 Human genes 0.000 claims 3
- 102100034349 Integrase Human genes 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 238000004806 packaging method and process Methods 0.000 claims 3
- 230000001177 retroviral effect Effects 0.000 claims 3
- 238000011144 upstream manufacturing Methods 0.000 claims 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100020873 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 101710128836 Large T antigen Proteins 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 239000006228 supernatant Substances 0.000 claims 2
- 101000782219 Bos taurus von Willebrand factor Proteins 0.000 claims 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims 1
- ALOBJFDJTMQQPW-ONGXEEELSA-N Gly-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CN ALOBJFDJTMQQPW-ONGXEEELSA-N 0.000 claims 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 1
- 101000884191 Homo sapiens Cyclin-G1 Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108060001084 Luciferase Proteins 0.000 claims 1
- 239000005089 Luciferase Substances 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001332 colony forming effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000005090 green fluorescent protein Substances 0.000 claims 1
- 102000049816 human CCNG1 Human genes 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46457103P | 2003-04-21 | 2003-04-21 | |
| PCT/US2004/012302 WO2004093810A2 (en) | 2003-04-21 | 2004-04-21 | Methods and compositions for treating disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009043222A Division JP2009112314A (ja) | 2003-04-21 | 2009-02-25 | 疾患を処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524057A JP2006524057A (ja) | 2006-10-26 |
| JP2006524057A5 true JP2006524057A5 (https=) | 2008-10-23 |
Family
ID=33310915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513191A Pending JP2006524057A (ja) | 2003-04-21 | 2004-04-21 | 疾患を処置するための方法および組成物 |
| JP2009043222A Pending JP2009112314A (ja) | 2003-04-21 | 2009-02-25 | 疾患を処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009043222A Pending JP2009112314A (ja) | 2003-04-21 | 2009-02-25 | 疾患を処置するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8052966B2 (https=) |
| EP (2) | EP2353389B1 (https=) |
| JP (2) | JP2006524057A (https=) |
| AT (1) | ATE513471T1 (https=) |
| CA (1) | CA2522359C (https=) |
| ES (1) | ES2366617T3 (https=) |
| WO (1) | WO2004093810A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002236517A1 (en) * | 2000-11-29 | 2002-06-11 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| WO2006116622A2 (en) * | 2005-04-27 | 2006-11-02 | Emiliem | Novel methods and devices for evaluating poisons |
| US7587843B2 (en) | 2006-06-06 | 2009-09-15 | Demers Alain P | Portable ice resurfacing device and method |
| DE102006035617A1 (de) * | 2006-07-31 | 2008-02-21 | Siemens Ag | Automatische Bestimmung von Tumorlast |
| AU2011278931A1 (en) * | 2010-07-16 | 2013-03-07 | Epeius Biotechnologies Corporation | Targeted nanoparticles for cancer and other disorders |
| AU2014236208B2 (en) * | 2013-03-14 | 2018-07-19 | Genvivo, Inc. | Thymidine kinase diagnostic assay for gene therapy applications |
| JP2017506097A (ja) | 2014-02-05 | 2017-03-02 | マフィン・インコーポレイテッドＭｕｆｆｉｎ Ｉｎｃｏｒｐｏｒａｔｅｄ | 区画された低温保存容器およびその使用 |
| ES2913205T3 (es) | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
| WO2020210829A1 (en) * | 2019-04-12 | 2020-10-15 | Gordon Erlinda M | Methods of promoting long-term survival of patients with advanced chemotherapy-resistant malignancies |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2595915A (en) * | 1947-04-18 | 1952-05-06 | Texas Co | Internal-combustion engine |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| WO1989009271A1 (en) | 1988-03-21 | 1989-10-05 | Viagene, Inc. | Recombinant retroviruses |
| US5591624A (en) * | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| CA2072581A1 (en) * | 1990-10-25 | 1992-04-26 | Clague Hodgson | Method of gene transfer using retrotransposons |
| US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| US6239351B1 (en) | 1993-07-01 | 2001-05-29 | Hoskins Manufacturing Company | Multi-wire self-diagnostic thermocouple |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| DE69515028T2 (de) * | 1994-03-22 | 2000-06-29 | The Immune Response Corp., Carlsbad | Die hocheffiziente herstellung und isolierung von viruspartikeln |
| US5643770A (en) * | 1994-07-21 | 1997-07-01 | Alexion Pharmaceuticals, Inc. | Retroviral vector particles expressing complement inhibitor activity |
| US6818439B1 (en) * | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| WO1996030504A1 (en) | 1995-03-24 | 1996-10-03 | Genetic Therapy, Inc. | Modified viral envelope polypeptide |
| US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| US5800811A (en) * | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
| US5976567A (en) | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US5980935A (en) | 1996-05-15 | 1999-11-09 | Kirpotin; Dmitri | Cationic lipids and methods of use therefor |
| DE69727984T2 (de) | 1996-07-09 | 2005-01-05 | Canji, Inc., San Diego | Verfahren zur messung viraler infektivität |
| US5962429A (en) | 1996-11-22 | 1999-10-05 | University Of Iowa | Complexes of adenovirus with cationic molecules |
| CA2595915A1 (en) | 1997-01-31 | 1998-08-06 | Schering Corporation | Methods for cultivating cells and propagating viruses |
| WO1998044938A1 (en) | 1997-04-10 | 1998-10-15 | University Of Southern California | Modified proteins which bind extracellular matrix components |
| US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
| JP2002508765A (ja) | 1997-06-23 | 2002-03-19 | アルザ コーポレイション | リポソーム被包ポリヌクレオチド組成物および方法 |
| US6110745A (en) | 1997-07-24 | 2000-08-29 | Inex Pharmaceuticals Corp. | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| FR2766706B1 (fr) | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| AU3402501A (en) | 2000-03-02 | 2001-09-12 | Univ Southern California | Mutated cyclin g1 protein |
| US7060811B2 (en) * | 2000-10-13 | 2006-06-13 | Board Of Regents, The University Of Texas System | WWOX: a tumor suppressor gene mutated in multiple cancers |
| AU2002236517A1 (en) * | 2000-11-29 | 2002-06-11 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| EP1421833A4 (en) * | 2001-08-30 | 2006-04-05 | Tolemac Llc | ANTIPROTONE PRODUCTION AND RELEASE FOR THE PRESENTATION AND TERMINATION OF UNWANTED CELLS |
| US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| US20070178066A1 (en) * | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| AU2005274905B2 (en) * | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| CN102801264B (zh) | 2012-09-04 | 2015-02-11 | 魏乐汉 | 永磁叠层电机 |
-
2004
- 2004-04-21 EP EP10011666.4A patent/EP2353389B1/en not_active Expired - Lifetime
- 2004-04-21 AT AT04760083T patent/ATE513471T1/de not_active IP Right Cessation
- 2004-04-21 EP EP04760083A patent/EP1619951B1/en not_active Expired - Lifetime
- 2004-04-21 JP JP2006513191A patent/JP2006524057A/ja active Pending
- 2004-04-21 WO PCT/US2004/012302 patent/WO2004093810A2/en not_active Ceased
- 2004-04-21 CA CA2522359A patent/CA2522359C/en not_active Expired - Lifetime
- 2004-04-21 US US10/829,926 patent/US8052966B2/en not_active Expired - Lifetime
- 2004-04-21 ES ES04760083T patent/ES2366617T3/es not_active Expired - Lifetime
-
2009
- 2009-02-25 JP JP2009043222A patent/JP2009112314A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7054694B2 (ja) | 誘導性カスパーゼおよび使用方法 | |
| CN105949324B (zh) | 靶向gpc3的嵌合抗原受体及其用途 | |
| CN108018299B (zh) | 靶向bcma的嵌合抗原受体及其用途 | |
| TWI232884B (en) | Enhanced virus-mediated DNA transfer | |
| WO1993014188A1 (en) | Targeted virus | |
| JP2001522236A (ja) | 改変アデノウイルスファイバーおよび標的アデノウイルス | |
| CN110923255B (zh) | 靶向bcma和cd19嵌合抗原受体及其用途 | |
| WO2021233346A1 (zh) | 一种被靶向修饰且装载有药物的外泌体及其制备方法和应用 | |
| JP2006524057A5 (https=) | ||
| WO2009013324A9 (en) | Vector particles for targeting cd34+ cells | |
| CN108004259A (zh) | 靶向b细胞成熟抗原的嵌合抗原受体及其用途 | |
| CN109320615A (zh) | 靶向新型bcma的嵌合抗原受体及其用途 | |
| CN114592010A (zh) | NK-CAR-MbIL-15细胞及其制备方法和应用 | |
| CN112813030A (zh) | 一种靶向fgfr4和dr5的嵌合抗原受体t细胞及其制备方法和应用 | |
| CN107446051A (zh) | 靶向cd19的嵌合抗原受体及其用途 | |
| CN107868792A (zh) | 靶向cd123的嵌合抗原受体及其用途 | |
| WO2024000223A1 (zh) | 经改造的病毒包膜蛋白及其用途 | |
| CN117919197A (zh) | 一种低免疫原性靶向囊泡递送系统及其制备方法与应用 | |
| JP2008507282A (ja) | 自己免疫および自己抗原に関連する疾患の特異的阻害 | |
| CN112226461B (zh) | Cd4阳性细胞特异性基因传递载体及其应用 | |
| JP2006508635A (ja) | 治療用または診断用試薬を送達するためのターゲティングタンパク質 | |
| CN116478932A (zh) | 基因修饰的免疫细胞及其应用 | |
| WO2026056440A1 (zh) | T细胞特异性膜融合型仿病毒颗粒及其制备方法和应用 | |
| WO1999026480A1 (en) | Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases | |
| CN105585637B (zh) | 基于il-12稳定膜表达的肿瘤治疗剂及其制法和用途 |